{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:01:01Z","timestamp":1792008061140,"version":"4.4.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.jhep.2018.05.009","type":"journal-article","created":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T17:23:20Z","timestamp":1536945800000},"page":"793-802","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":103,"title":["Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B"],"prefix":"10.1016","volume":"69","author":[{"given":"Grace Lai-Hung","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry Lik-Yuen","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee-Kit","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry Cheuk-Fung","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin Long-Yan","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace Chung-Yan","family":"Lui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent Wai-Sun","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2018.05.009_b0005","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.05.009_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2018.05.009_b0015","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.05.009_b0020","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1111\/j.1572-0241.2000.03373.x","article-title":"Risk factors for active liver disease in HBeAg-negative chronic hepatitis B virus-infected patients","volume":"95","author":"Chan","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2018.05.009_b0025","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1111\/j.1572-0241.2008.02157.x","article-title":"Evaluation of alanine transaminase and hepatitis B virus DNA to predict liver cirrhosis in hepatitis B e antigen-negative chronic hepatitis B using transient elastography","volume":"103","author":"Wong","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2018.05.009_b0030","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1053\/j.gastro.2013.02.002","article-title":"Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment","volume":"144","author":"Wong","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2018.05.009_b0035","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide vs. tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Buti","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2018.05.009_b0040","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"Tenofovir alafenamide vs. tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Chan","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2018.05.009_b0045","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40265-017-0754-9","article-title":"Tenofovir alafenamide: a review in chronic hepatitis B","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.jhep.2018.05.009_b0050","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2018.05.009_b0055","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/j.1365-2036.2012.05098.x","article-title":"Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years","volume":"35","author":"Wong","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2018.05.009_b0060","doi-asserted-by":"crossref","first-page":"S478","DOI":"10.1016\/S0168-8278(17)31347-8","article-title":"A phase 3 study comparing tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate in patients with HBeAg-positive, chronic hepatitis B (CHB): efficacy and safety results at 96 weeks","volume":"66","author":"Agarwal","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.05.009_b0065","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jhep.2011.09.013","article-title":"Hepatitis B virus infection and fatty liver in the general population","volume":"56","author":"Wong","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.05.009_b0070","article-title":"Development Journey of Clinical Data Analysis and Reporting System (CDARS) in Hospital Authority of Hong Kong","volume":"1468","author":"Cheng","year":"2010","journal-title":"MEDINFO"},{"key":"10.1016\/j.jhep.2018.05.009_b0075","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.jhep.2017.06.019","article-title":"Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance","volume":"67","author":"Yip","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.05.009_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(13)60046-X","article-title":"Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis","author":"Wong","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.05.009_b0085","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/apt.14172","article-title":"Laboratory parameter-based machine learning model for excluding non-alcoholic fatty liver disease (NAFLD) in the general population","volume":"46","author":"Yip","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2018.05.009_b0090","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/apt.14341","article-title":"Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis","volume":"46","author":"Wong","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2018.05.009_b0095","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2015.11.035","article-title":"PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy","volume":"64","author":"Papatheodoridis","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.05.009_b0100","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1200\/JCO.2009.26.2675","article-title":"Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers","volume":"28","author":"Wong","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2018.05.009_b0105","first-page":"40","article-title":"De Ritis ratio as diagnostic marker of alcoholic liver disease","volume":"8","author":"Majhi","year":"2006","journal-title":"Nepal Med Coll J"},{"key":"10.1016\/j.jhep.2018.05.009_b0110","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.cgh.2009.05.025","article-title":"Surrogate end points and long-term outcome in patients with chronic hepatitis B","volume":"7","author":"Wong","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2018.05.009_b0115","first-page":"914","article-title":"Features of the metabolic syndrome are associated with lack of serum ALT normalization during therapy for chronic hepatitis B","volume":"64","author":"Fung","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.05.009_b0120","first-page":"917A","article-title":"Correlation of early biochemical and virologic responses during oral antiviral therapy for chronic hepatitis B","volume":"64","author":"Brunetto","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.05.009_b0125","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/apt.12658","article-title":"Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B\u2013a prospective cohort study with paired transient elastography examinations","volume":"39","author":"Wong","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2018.05.009_b0130","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1136\/gut.2008.157735","article-title":"Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B","volume":"58","author":"Wong","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2018.05.009_b0135","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/hep.28778","article-title":"Metabolic syndrome increases cardiovascular events but not hepatic events and death in patients with chronic hepatitis B","volume":"64","author":"Cheng","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.05.009_b0140","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.jhep.2015.07.009","article-title":"Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: a propensity score landmark analysis","volume":"63","author":"Hsiang","year":"2015","journal-title":"J Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827818320555?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827818320555?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T12:14:55Z","timestamp":1662034495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827818320555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0168827818320555"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2018.05.009","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2018.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}